Forest plot illustrating risk factors for major bleeding and arterial or venous event in MF. The model is adjusted for age, sex, presence of JAK2 V617F mutation, levels of Hb, WBC count, platelet count, previous thrombotic event or bleeding, symptom-directed therapy, and antithrombotic treatment. DOACs, direct oral anticoagulants; ESA, erythropoietin-stimulating agent; IMiDs, immunomodulatory drugs; LMWH, low-molecular weight heparin, VTE, venous thromboembolism.